The charts show that this is going to 10+ in very short order. The stock was hit first by the departure of the executive, and then disappointment by the survival time extension in the lung cancer trial. Both were overdone moves, especially when management stepped in to buy shares. But then the breast cancer breakthrough results came in, and that was never in the share price, and has to be discounted into a higher valuation. So we go back to where we were in the Spring, and even higher.